Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

191.43USD
4:00pm EDT
Change (% chg)

$-3.01 (-1.55%)
Prev Close
$194.44
Open
$193.12
Day's High
$193.67
Day's Low
$189.81
Volume
341,400
Avg. Vol
739,176
52-wk High
$270.63
52-wk Low
$147.73

SHPG.OQ

Chart for SHPG.OQ

About

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $57,888.79
Shares Outstanding(Mil.): 299.63
Dividend: 0.66
Yield (%): 0.70

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 28.82 35.76 36.62
EPS (TTM): 6.75 -- --
ROI: 8.21 15.33 14.52
ROE: 13.84 16.37 15.68

BRIEF-Shire U.S. launch of Xiidra planned for Q3 2016

July 12 Shire Plc * U.S. launch of Xiidra planned for Q3 2016 Source text for Eikon: Further company coverage:

Jul 12 2016

UPDATE 2-Shire on a roll as U.S. approves keenly awaited eye drug

* CEO to update on Baxalta cost savings next month (Adds comments by CEO on sales outside U.S., Baxalta synergies)

Jul 12 2016

Shire CEO to update on Baxalta savings next month

LONDON Shire's chief executive said on Tuesday the drugmaker would give an update on savings from the acquisition of Baxalta when it reports second-quarter results on August 2, raising hopes that more costs will be eliminated than initially forecast.

Jul 12 2016

Shire on a roll as U.S. approves keenly awaited eye drug

Shire has won U.S. approval for its most important new medicine, a treatment for dry eyes, in a fresh boost for the company which completed its $32 billion acquisition of U.S. rare diseases specialist Baxalta last month.

Jul 12 2016

European shares edge up for fourth straight session

LONDON, July 12 European shares edged higher on Tuesday, boosted by a rise in Shire after positive drug trial results, with Daimler also gaining after its quarterly results.

Jul 12 2016

FDA approves Shire's keenly-watched eye drug

July 11 The U.S. Food and Drug Administration on Monday approved Shire Plc's lifitegrast eye drops for treating signs and symptoms of dry eye disease, allowing the company to bring to market its most important pipeline medicine.

Jul 11 2016

BRIEF-Shire says FDA approves Shire's Xiidra

* Shire expects to launch Xiidra in United States in Q3 of 2016

Jul 11 2016

BRIEF-Shire reports results for mid-stage trial of shp607 in extremely premature infants

* Shire announces top-line results for phase 2 trial of shp607 in extremely premature infants Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 30 2016

CORRECTED-UPDATE 1-Shire says ADHD drug meets main goal of study (June 29)

June 29 Irish drugmaker Shire Plc said a study testing an experimental drug to treat attention-deficit disorder met the main goal, bringing the drug one step closer to approval in the United States.

Jun 30 2016

BRIEF-Shire announces positive topline results of SHP465 efficacy and safety study

* Shire announces positive topline results of SHP465 efficacy and safety study in adults with ADHD

Jun 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.